{
    "clinical_study": {
        "@rank": "94204", 
        "arm_group": [
            {
                "arm_group_label": "Aspirin", 
                "arm_group_type": "Active Comparator", 
                "description": "Twenty eight enteric coated 81mg Aspirin tablets will be dispensed for daily oral dosing, to be taken with a meal at the same time of day."
            }, 
            {
                "arm_group_label": "Omega-3 Free Fatty Acids", 
                "arm_group_type": "Active Comparator", 
                "description": "Three hundred thirty-six gelatin coated  450 mg capsules containing approximately 180 mg of EPA and 135 mg of DHA will be dispensed. Patients are to take 12 capsules daily with meals, either once daily (12 capsules with one meal) or divided twice daily (e.g., six with breakfast and six with dinner)."
            }, 
            {
                "arm_group_label": "Aspirin & Omega-3 FFAs", 
                "arm_group_type": "Active Comparator", 
                "description": "Aspirin (81 mg po daily) to be taken simultaneously with Omega-3 Free Fatty Acids (1500mg of docosahexaoic acid (DHA) and 2500mg eicosapentanoic acid (EPA) given daily."
            }
        ], 
        "brief_summary": {
            "textblock": "Obesity promotes worse outcome for post-menopausal breast cancer patients."
        }, 
        "brief_title": "Impact of COX2 on Sera Biomarkers From Obese Subjects", 
        "completion_date": {
            "#text": "August 2015", 
            "@type": "Anticipated"
        }, 
        "condition": "Breast Cancer Survivors", 
        "condition_browse": {
            "mesh_term": "Breast Neoplasms"
        }, 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion Criteria:\n\n          -  At least 18 years of age\n\n          -  Post-menopausal as confirmed by medical history\n\n          -  Ability to understand the purposes and risks of the study and has signed a written\n             informed consent form approved by the investigator's IRB/Ethics Committee\n\n        Exclusion Criteria:\n\n          -  Evidence of active cancer (patients with a prior history of malignancy are encouraged\n             to participate, but due to cytokine levels associated with malignancy there must be\n             no evidence of disease)\n\n          -  Cachexia\n\n          -  Active systemic illness (infection including viral illnesses such as Hepatitis and\n             HIV)\n\n          -  Chronic use of aspirin of omega-3 free fatty acid supplementation within the last 60\n             days (defined as greater than or equal to 7 consecutive days)\n\n          -  Known hypersensitivity to aspirin and/or omega-3 fatty acids\n\n          -  Actively receiving a physician-directed regimen of aspirin and/or receiving\n             herapeutic/prophylactic anticoagulation\n\n          -  Any aspirin or omega-3 free fatty acid supplementation within the last 14 days\n\n          -  Subjects who are pregnant\n\n          -  History of medical noncompliance"
            }, 
            "gender": "Female", 
            "healthy_volunteers": "Accepts Healthy Volunteers", 
            "maximum_age": "N/A", 
            "minimum_age": "18 Years"
        }, 
        "enrollment": {
            "#text": "120", 
            "@type": "Anticipated"
        }, 
        "firstreceived_date": "December 9, 2013", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT02062255", 
            "org_study_id": "CTRC 13-0041", 
            "secondary_id": "HSC20130426H"
        }, 
        "intervention": [
            {
                "arm_group_label": [
                    "Aspirin", 
                    "Aspirin & Omega-3 FFAs"
                ], 
                "intervention_name": "Aspirin", 
                "intervention_type": "Drug"
            }, 
            {
                "arm_group_label": [
                    "Omega-3 Free Fatty Acids", 
                    "Aspirin & Omega-3 FFAs"
                ], 
                "intervention_name": "Omega 3 FFA", 
                "intervention_type": "Dietary Supplement"
            }
        ], 
        "intervention_browse": {
            "mesh_term": "Aspirin"
        }, 
        "is_fda_regulated": "Yes", 
        "is_section_801": "Yes", 
        "keyword": [
            "Asprin", 
            "Omega-3 Free Fatty Acids", 
            "Obesity", 
            "COX-2 inhibitor"
        ], 
        "lastchanged_date": "February 11, 2014", 
        "location": {
            "contact": {
                "email": "goodwine@uthscsa.edu", 
                "last_name": "Epp Goodwin", 
                "phone": "210-450-5798"
            }, 
            "facility": {
                "address": {
                    "city": "San Antonio", 
                    "country": "United States", 
                    "state": "Texas", 
                    "zip": "78229"
                }, 
                "name": "Cancer Therapy and Research Center at UTHSCSA"
            }, 
            "investigator": {
                "last_name": "Andrew Brenner, MD", 
                "role": "Principal Investigator"
            }, 
            "status": "Recruiting"
        }, 
        "location_countries": {
            "country": "United States"
        }, 
        "number_of_arms": "3", 
        "official_title": "A Phase 0, Investigator Initiated Study, Evaluating the Impact of COX2 Inhibition on Human Sera Biomarkers From Obese Subjects", 
        "overall_contact": {
            "email": "goodwine@uthscsa.edu", 
            "last_name": "Epp Goodwin", 
            "phone": "210-450-5798"
        }, 
        "overall_official": {
            "affiliation": "The University of Texas Health Science Center at San Antonio", 
            "last_name": "Andrew Brenner, MD", 
            "role": "Principal Investigator"
        }, 
        "overall_status": "Recruiting", 
        "oversight_info": {
            "authority": [
                "United States: Food and Drug Administration", 
                "United States: Institutional Review Board"
            ], 
            "has_dmc": "Yes"
        }, 
        "phase": "Phase 0", 
        "primary_completion_date": {
            "#text": "August 2015", 
            "@type": "Anticipated"
        }, 
        "primary_outcome": {
            "description": "Blood levels of Prostaglandin E2, aromatase, pro-inflammatory cytokines, steroids, and lipids will be measured pre and post treatment.", 
            "measure": "Biomarker levels", 
            "safety_issue": "No", 
            "time_frame": "29 days"
        }, 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT02062255"
        }, 
        "responsible_party": {
            "investigator_affiliation": "The University of Texas Health Science Center at San Antonio", 
            "investigator_full_name": "Andrew Brenner", 
            "investigator_title": "Principal Investigator", 
            "responsible_party_type": "Principal Investigator"
        }, 
        "secondary_outcome": {
            "description": "Correlation for body mass index impact on response to COX2 inhibition.", 
            "measure": "BMI", 
            "safety_issue": "No", 
            "time_frame": "29 Days"
        }, 
        "source": "The University of Texas Health Science Center at San Antonio", 
        "sponsors": {
            "lead_sponsor": {
                "agency": "The University of Texas Health Science Center at San Antonio", 
                "agency_class": "Other"
            }
        }, 
        "start_date": "October 2013", 
        "study_design": "Allocation: Randomized, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Basic Science", 
        "study_type": "Interventional", 
        "verification_date": "February 2014"
    }
}